Events

Rappel de Guardian Connect Mobile App

Selon Department of Health, Therapeutic Goods Administration, ce/cet/cette rappel concerne un dispositif en/au/aux/à Australia qui a été fabriqué par Medtronic Australasia Pty Ltd.

Qu'est-ce que c'est?

Une correction ou un retrait opéré par un fabricant afin de répondre à un problème causé par un dispositif médical. Les rappels surviennent lorsqu'un dispositif médical est défectueux, lorsqu'il pourrait poser un risque pour la santé, ou les deux à la fois.

En savoir plus sur les données ici
  • Type d'événement
    Recall
  • ID de l'événement
    RC-2018-RN-00882-1
  • Classe de risque de l'événement
    Class II
  • Date de mise en oeuvre de l'événement
    2018-07-04
  • Pays de l'événement
    Australia
  • Source de l'événement
    DHTGA
  • URL de la source de l'événement
    https://apps.tga.gov.au/Prod/sara/arn-detail.aspx?k=RC-2018-RN-00882-1
  • Notes / Alertes
    Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
  • Notes supplémentaires dans les données
  • Cause
    Medtronic has identified an issue in apple ios 11.3 & 11.4 that can sometimes prevent patients from receiving a 'lost communication' alert after their guardian connect app is closed by the iphone's operating system (ios) in certain situations. the operating system may close the guardian connect app without alerting patients that the app is no longer running or communicating with the guardian connect transmitter. if the app is closed, patients will not receive alerts that could be associated with hypoglycaemic or hyperglycaemic events. medtronic have received reports from patients regarding the app closing without warning, however, to date, no reports of injury as a result of this issue have been received.
  • Action
    Medtronic is advising users to immediately update their Guardian Connect App to the latest release (v3.2.2) located on the App Store. Medtronic also reminds users that as described in the App User Guide, Medtronic cannot guarantee that iPhones will always allow for the Guardian Connect App to run in the background. If the iPhone automatically closes your Guardian Connect App, users may receive a ‘Lost Communication’ alert. To ensure users continue receiving sensor glucose data and alerts, Medtronic recommends periodically checking that the Guardian Connect App is still running, being especially mindful of this anomaly when running several applications at once or after using gaming and video Apps which use a lot of the iPhone’s power or memory resources.

Device

Guardian Connect Mobile App
  • Modèle / numéro de série
    Guardian Connect Mobile AppPart number: CSS7200 ARTG Number : 276924(Medtronic Australasia Pty Ltd - Information system software, application program, patient record)
  • Manufacturer
    Medtronic Australasia Pty Ltd

Manufacturer

Medtronic Australasia Pty Ltd
  • Société-mère du fabricant (2017)
    Medtronic plc
  • Commentaire du fabricant
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    DHTGA